Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VELIPARIB: 391 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
391
Total FAERS Reports
43 (11.0%)
Deaths Reported
222
Hospitalizations
391
As Primary/Secondary Suspect
23
Life-Threatening
3
Disabilities

First Report: 20091223 · Latest Report: 20190901

What Are the Most Common VELIPARIB Side Effects?

#1 Most Reported
Neutrophil count decreased
124 reports (31.7%)
#2 Most Reported
Anaemia
118 reports (30.2%)
#3 Most Reported
White blood cell count decreased
94 reports (24.0%)

All VELIPARIB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Neutrophil count decreased 124 31.7% 7 67
Anaemia 118 30.2% 6 63
White blood cell count decreased 94 24.0% 6 53
Febrile neutropenia 76 19.4% 0 69
Platelet count decreased 70 17.9% 6 37
Hypertension 57 14.6% 3 33
Nausea 46 11.8% 2 38
Hyponatraemia 38 9.7% 4 22
Vomiting 36 9.2% 1 30
Hypokalaemia 31 7.9% 3 25
Dehydration 29 7.4% 4 25
Abdominal pain 24 6.1% 1 23
Diarrhoea 23 5.9% 1 20
Fatigue 23 5.9% 0 16
Embolism 19 4.9% 1 13
Blood creatinine increased 18 4.6% 2 5
Dyspnoea 18 4.6% 2 11
Sepsis 17 4.4% 9 11
Syncope 17 4.4% 1 12
Neutropenia 16 4.1% 5 10

Who Reports VELIPARIB Side Effects? Age & Gender Data

Gender: 92.3% female, 7.7% male. Average age: 57.9 years. Most reports from: US. View detailed demographics →

Is VELIPARIB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2009 1 0 1
2010 1 1 1
2011 5 0 2
2012 16 1 13
2013 11 1 9
2014 28 1 24
2015 139 10 127
2016 35 6 29
2017 5 1 4
2018 9 0 7
2019 1 0 1

View full timeline →

What Is VELIPARIB Used For?

IndicationReports
Ovarian epithelial cancer 97
Triple negative breast cancer 67
Colorectal cancer 39
Breast cancer 24
Fallopian tube cancer 21
Ovarian cancer 16
Colorectal cancer metastatic 14
Malignant peritoneal neoplasm 11
Neoplasm 9
Breast cancer metastatic 8

VELIPARIB vs Alternatives: Which Is Safer?

VELIPARIB vs VEMURAFENIB VELIPARIB vs VENETOCLAX VELIPARIB vs VENLAFAXINE VELIPARIB vs VENTAVIS VELIPARIB vs VENTOLIN VELIPARIB vs VENTOLIN HFA VELIPARIB vs VERAPAMIL VELIPARIB vs VERICIGUAT VELIPARIB vs VERTEPORFIN VELIPARIB vs VESICARE

Official FDA Label for VELIPARIB

Official prescribing information from the FDA-approved drug label.